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Organocatalytic Enantioselective Synthesis of Pyrazoles Bearing 
a Quaternary Stereocenter 
Carlos Vila,*[a] Fares Ibrahim Amr,[a] Gonzalo Blay,[a] M. Carmen Muñoz,[b] and José R. Pedro*[a] 
Abstract: An efficient one-pot asymmetric synthesis of pyrazoles 
bearing a chiral quaternary stereocenter has been developed. Quinine 
derived thiourea catalyzed the enantioselective addition of 
pyrazolones to isatin-derived ketimines providing the corresponding 
acetylated pyrazoles after in situ treatment with Ac2O/Et3N. The 
corresponding pyrazoles were afforded with high yields and excellent 
enantioselectivities. 
Introduction 
Five-membered nitrogen heterocycles have been recognized as 
privileged structural frameworks for the development of molecules 
with biological and pharmaceutical properties. Among the various 
five-membered nitrogen heterocycles, pyrazole, containing two 
adjacent nitrogen atoms, represent an important class of aromatic 
heterocycle that recently have attracted huge attention because 
of the wide applications in medicinal, pharmaceutical, 
agrochemical or coordination chemistry.[1] For example, pyrazole 
ring is a scaffold present in blockbuster drugs such celecoxib and 
sildenafil, or in a proposed drug such remogliflozin etabonate[2] 
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Figure 1. Representative pharmaceutical active pyrazoles. 
In view of the great importance of the pyrazole skeleton, the 
asymmetric synthesis of pyrazoles bearing stereocenters have 
become an attractive goal and many and efficient synthetic 
approaches have been established.[3] Among them, the addition 
of pyrazolone to different electrophiles and posterior acetylation 
or annulation represents a valuable methodology.[4,5] 
Nevertheless, 1,2-addition reactions of pyrazolone for the 
synthesis of chiral pyrazoles have not been described as far as 
we know. 
On the other hand, the oxindole moiety constitutes an important 
and privileged scaffold present in numerous natural products and 
pharmacologically active compounds.[6] One way to prepare 
enantioenriched amino oxindole adducts is the asymmetric 
addition of nucleophiles to isatin-derived ketimines.[7] Given the 
relevance of pyrazole and amino oxindoles,[8] it was anticipated 
that the incorporation of both structural motifs into one molecule 
could result in a novel chiral pyrazoles bearing a quaternary 
stereocenter with potentially interesting biological properties 






























Scheme 1. Relevance of pyrazole-amino oxindole adducts. 
As a part of our ongoing interest in the asymmetric synthesis of 
nitrogen aromatic heterocycles bearing a quaternary 
stereocenter[10] and the synthesis of optically pure amino oxindole 
compounds,[11] here we described the highly enantioselective 
addition of pyrazolone to isatin-derived ketimines,[12] providing a 
novel pyrazole adducts after acetylation of the pyrazolone moiety. 
Results and Discussion 
We initiated our studies by evaluating the reaction between 
isatin-derived N-Boc ketimine 1a and 5-methyl-2-phenyl-2,4-
dihydro-3H-pyrazol-3-one  (2a) in the presence of a series of 
bifunctional organocatalysts.[13]  We thought in the use of 
bifunctional organocatalysts with a hydrogen bonding donor 
moiety in order to activate the electrophile (the isatin-derived N-
Boc ketimine), and a tertiary amine responsible for the activation 
of the nucleophile (the pyrazolone). As shown in Table 1, when 5 
mol% of quinine (Cat-1) was used in toluene, full conversion to 
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the addition product was obtained within 5 hours. However, the 
analysis by NMR spectroscopy indicated that the addition product 
was a mixture of tautomers and diastereomers. Fortunately, this 
mixture could be in situ acetylated with Et3N/Ac2O, affording the 
corresponding pyrazole-amino oxindole adduct 3aa in 82% yield, 
but with low enantioselectivity (29% ee, entry 1 Table 1).  
 
Table 1. Optimization of the reaction conditions.  
Entry[a] Catalyst (x mol%) t (h) Yield (%)[b] Ee (%)[c]  
1 Cat-1 (5 mol%) 5 82 29 
2 Cat-2 (5 mol%) 5 92 15[d] 
3 Cat-3 (5 mol%) 7 74 31[d] 
4 Cat-4 (5 mol%) 5 94 8[d] 
5 Cat-5 (5 mol%) 2 82 99 
6 Cat-6 (5 mol%) 2 92 97 
7 Cat-7 (5 mol%) 3,5 91 98[d] 
8 Cat-5 (2 mol%) 3,5 98 99 
9 Cat-5 (1 mol%) 3,5 95 99 
[a] Reaction conditions: 1a (0.1 mmol), 2a (0.1 mmol) and catalyst (x mol%) 
in 1 mL of toluene at rt. [b] Isolated yield after column chromatography. [c]
 
Determined by HPLC using chiral stationary phase. [d] Opposite enantiomer 
was obtained.  
 
With quinidine (Cat-2, entry 2), a slightly better yield was obtained 
(92 %), but a lower enantiomeric excess of the opposite 
enantiomer was observed (15% ee). Cupreine derivatives Cat-3 
and Cat-4, could catalyze the reaction but product 3aa was 
obtained with poor enantioselectivities (entry 3 and 4, 
respectively). To our delight, quinine derived thiourea Cat-5,[14] 
exhibited excellent reactivity with high enantioselectivity, affording 
product 3aa with an excellent enantiomeric excess of 99% (entry 
5). Quinine derived squaramide Cat-6,[15] could promote the 
reaction with high stereocontrol and good yield, although with 
slightly lower enantiomeric excess than Cat-5 (entry 6). 
Interestingly, when Takemoto’s catalyst[16] Cat-7 was used 
product 3aa was obtained with high yield and excellent 
enantioselectivity (98% ee), but to the opposite enantiomer (entry 
7). With thiourea Cat-4, we screened the catalyst loading and we 
found that we could decrease the catalyst loading to only 1 mol% 
without compromising the yield and enantiomeric excess (entry 9). 
With the optimized reaction conditions stablished, the scope of 
the reaction was explored with respect to both the isatin-derived 
N-Boc ketimines and the pyrazolone. First we tested different 
isatin-derived ketimines with pyrazolone 2a (Scheme 2). Initially, 
N-substitution of the oxindole nitrogen was evaluated (Scheme 2, 
3aa-3da). Groups such as benzyl, methyl or allyl were well 
tolerated providing the corresponding adducts with excellent 
enantioselectivities (98-99% ee). In addition, a non-protected free 
NH on the oxindole ring was also tolerated (3da), which allows for 
facile potential N-substitutions on demand. Electron-donating 
(MeO) or electron-withdrawing (Cl or NO2), were tolerated at the 
5 position of the isatin-derived ketimine, affording the 
corresponding products (3ea-3ga) with good yields and high 
stereocontrol. Moreover, ketimines with substituents at 6 or 7 
positions reacted smoothly, providing pyrazoles 3ha and 3ia with 
very good results. 



















































































































Scheme 2. Scope for different isatin derived ketimines: 1 (0.05 mmol), 2a (0.051 
mmol) and Cat-5 (1 mol%) in 1 mL of toluene. Isolated yields after column 
chromatography. Enantiomeric excesses were determined by HPLC using 
chiral stationary phase. 





Different pyrazolones 2 were also evaluated in the reaction with 
isatin-derived N-Boc ketimine 1a (Scheme 3). The reaction 
proceeded efficiently with pyrazolones with diverse substituents 
(MeO or Cl) on the N-aryl group. Moreover, when 2,5-diphenyl-
pyrazolone was tested the corresponding product 3ad was 
afforded with 98% yield and 97% ee. Once we studied different 
substituted pyrazolones, we turned our attention on the trapping 
agent for the enol form of the pyrazolone moiety. After the addition 
of pyrazolone 2a to the ketimine 1a was completed, benzoyl 
chloride (BzCl) and Et3N were added to the reaction mixture and 
the corresponding chiral pyrazole 3af was afforded with excellent 
yield (97%) and enantioselectivity (99% ee). Similarly, when 
mesyl chloride (MsCl) was used for the second step, the 
corresponding mesylated pyrazole 3ag was obtained with high 
yield and enantiomeric excess. On the contrary, when ethyl 
chloroformate was used, the reactivity was lower and the product 
3ah was gained with lower yield (62%), although with excellent 
enantioselectivity (98% ee). 

































































































Scheme 3. Scope for different pyrazolones: 1a (0.05 mmol), 2 (0.051 mmol) 
and Cat-5 (1 mol%) in 1 mL of toluene. Isolated yields after column 
chromatography. Enantiomeric excesses were determined by HPLC using 
chiral stationary phase. a Ac2O (1 eq.) was used for the second step. b BzCl (2 
eq.) was used for the second step. c MsCl (2 eq.) was used for the second step. 
d ClCO2Et (2 eq.) was used for the second step. 
The absolute configuration of the stereogenic center in compound 
3ha was determined to be (R) on the basis of X-ray 
crystallographic analysis (Figure 2);[17] the configuration of the 




Figure 2. X-ray crystal structure of 3ha. 
A plausible transition-state model for the enantioselective reaction 
is shown in Scheme 4. The thiourea catalyst is responsible for the 
preorientation and activation of the substrates acting as a 
bifunctional organocatalyst. The isatin-derived N-Boc ketimine is 
activated upon formation of hydrogen bonds between the thiourea 
moiety and the N-Boc and the carbonyl groups of the oxindole, 
while at the same time the pyrazolone undergoes nucleophilic 
activation by hydrogen bonding with the quinuclidine moiety of the 
catalyst.[5a-b,18] The pyrazolone 2 will attack to the Re-face of the 
ketimine, thus accounting for the observed enantioselectivity. The 
corresponding acetylated pyrazoles 3 are obtained after in situ 







































Scheme 4. Plausible transition-state model. 
Conclusions 
In conclusion, we have successfully developed a thiourea derived 
quinine catalyzed enantioselective addition of pyrazolones to 
isatin-derived ketimines. The corresponding acetylated pyrazoles 
bearing a tetrasubstituted stereocenter were obtained in good 
yields (up to 98%) and excellent enantioselectivities (up to 99% 
ee). Furthermore, the enol form of the pyrazolone product could 
be trapped with different agents as Ac2O, BzCl, MsCl or ClCO2Et. 
This organocatalytic methodology provides access to chiral 





heterocyclic compounds bearing pyrazole and aminooxindole 
moieties, which possess potential pharmaceutical activities. 
Experimental Section 
General procedure for the enantioselective reaction 
A test tube containing ketimine 1a (0.1 mmol), pyrazolone 2a (0.1 mmol) 
and thiourea Cat-5 (0.6 mg, 0.001 mmol) was purged with N2. Then, 1.0 
mL of toluene was added and the mixture stirred at room temperature until 
the reaction was complete (TLC). After the reaction was complete, Ac2O 
(0.1 mmol) and Et3N (0.03 mmol), were added and the reaction mixture 
was stirred for 30 additional minutes. Finally, the reaction mixture was 
directly poured to the column chromatography, using hexane:EtOAc (95:5) 
as eluent to afford product 3aa. 
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